Results 111 to 120 of about 31,861 (267)

A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial [PDF]

, 2020
Suzie Cro, Prakash A. Patel, Jonathan Barker, David Burden, C.E.M. Griffiths, Helen J. Lachmann, Nick J. Reynolds, Richard B. Warren, Francesca Capon, Catherine Smith, Victoria Cornelius   +10 more
openalex   +1 more source

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center [PDF]

, 2023
Murat Bektaş, Servet Yüce, Mustafa Ay, Muhammed Hamdi Uyar, Mustafa Erkut Önder, Muhammed İkbal Kılıç   +5 more
openalex   +1 more source

Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching

Pediatric Dermatology, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to ...
Shaliz Aflatooni, Andrea Ure, Kimberly Smart, Julian A. Cortes, Gabriela Palma, Nicole Johnsen, Yvonne Nong, April W. Armstrong   +7 more
wiley   +1 more source

Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers [PDF]

, 2016
Background: Adult-onset Still's disease (AOSD) is rare inflammatory disease of unknown etiology that usually affects young adults. The more common clinical manifestations are spiking fevers, arthritis, evanescent rash, elevated liver enzymes ...
Berardicurti O., Carubbi F., Ciccia F., Cipriani P., Di Benedetto P., Giacomelli R., Guggino G., Iacono D., Liakouli V., Masedu F., Ruscitti P., Triolo G., Valenti M., Valentini G.   +13 more
core   +1 more source

Adjunctive Therapeutic Plasma Exchange in Refractory Adult‐Onset Still's Disease Complicated by Secondary Macrophage Activation Syndrome: A Single‐Center Experience

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 389-396, June 2026.
ABSTRACT Introduction Adult‐onset Still's disease (AOSD) complicated by macrophage activation syndrome (MAS) carries substantial mortality. The role of therapeutic plasma exchange (TPE) remains uncertain. Methods We retrospectively analyzed patients with AOSD‐MAS treated with TPE at a single‐center.
Masataka Ueda, Tomohiro Saito, Masahide Mizobuchi, Tomoki Shimomura, Saki Kawamori, Mitsuru Kawanishi, Natsuko Hattori, Jo Sugiyama, Satoshi Tsubata, Hanami Horiguchi, Kazuki Abe, Nao Iida, Yuki Kajio, Nao Oguro, Ryo Yanai, Hirokazu Honda   +15 more
wiley   +1 more source

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Drug Design, Development and Therapy, 2014
Dongsheng Hong,1 Zhihai Yang,1 Shuyin Han,1 Xingguang Liang,1 Kuifen Ma,1 Xingguo Zhang1,2 1Department of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, 2College of Pharmaceutical Science, Zhejiang Chinese Medical ...
Hong D, Yang Z, Han SY, Liang X, Ma K, Zhang X   +5 more
doaj  

Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim–Chester disease refractory to anakinra: successful use of vemurafenib: Fig. 1 [PDF]

, 2015
Jan Henrik Schirmer, Christoph Thorns, Frank Moosig, Julia U. Holle   +3 more
openalex   +1 more source

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson, Sophie L. Allen, Jonathan I. Quinlan, Amritpal Dhaliwal, Michael Macleod, Joshua Price, Jon Hazeldine, Michael S. Sagmeister, Caitlin Ditchfield, Kirsty C. McGee, Felicity R. Williams, Ahmed M. Elsharkawy, Matthew J. Armstrong, Carolyn A. Greig, Janet M. Lord, Leigh Breen, Simon W. Jones   +16 more
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B‐Cell‐Specific Somatic MYD88 Mutation

Allergy, EarlyView.
Yuyi Zhou, Yoko Ueki, Naoya Iwata, Hiroshi Oue, Kentaro Kato, Mengyan Li, Kazushi Izawa, Tomoyasu Jo, Seishi Ogawa, Kenji Kabashima, Naotomo Kambe   +10 more
wiley   +1 more source